Jardiance Dosage/Direction for Use

Type 2 diabetes mellitus: The recommended starting dose of Empagliflozin (Jardiance) is 10 mg once daily.
In patients tolerating empagliflozin 10 mg once daily who have an eGFR ≥30 mL/min/1.73 m² and requiring additional glycaemic control, the dose can be increased to 25 mg once daily.
Heart failure: The recommended dose of Empagliflozin (Jardiance) is 10 mg once daily (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions).
Chronic kidney disease: The recommended dose of Empagliflozin (Jardiance) is 10 mg once daily (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions).
Empagliflozin (Jardiance) can be taken with or without food.
Patients with renal impairment: Empagliflozin 10 mg can be used regardless of renal function. However, due to limited experience, it is not recommended to initiate treatment with Empagliflozin (Jardiance) in patients on dialysis.
Glycaemic efficacy of empagliflozin is dependent on renal function and likely absent in patients with severe renal impairment. If eGFR falls below 30 ml/min/1.73 m² the recommended dose of empagliflozin is limited to 10 mg and additional glucose lowering treatment should be considered if needed (see Precautions).
Patients with hepatic impairment: No dose adjustment is recommended for patients with hepatic impairment.
Elderly Patients: No dosage adjustment is recommended based on age.
Combination therapy: When Empagliflozin (Jardiance) is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia. (See Interactions and Adverse Reactions).
Missed dose: If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.
Paediatric population: Safety and effectiveness of Empagliflozin (Jardiance) in children under 18 years of age have not been established.